BESPONSA with trademark number 1755568 was lodged on 29/02/2016 and has a status of Accepted . The applicant/owner of the trademark is registered as Pfizer Inc... Besponsa is used to treat adults with acute lymphoblastic leukaemia (ALL). ALL is a cancer of the blood where the cells that help protect your body from infection and foreign materials (white blood cells) grow uncontrollably.. The Australian Medical Association has been pushing for the federal government to come to the party on providing funds to help GPs work with hospitals to manage complex patients.. The trial was conducted in United States, Canada, European Union, Japan, Korea, Singapore, Taiwan and Australia. Figure 1 summarizes how many men and women were in the clinical trial. Figure 1.. Besponsa, a medicine for people with acute leukaemia, currently costs $120,000 per course. After listing, it will cost $6.50 per script for concession card holders and about $40 for general . Moda Health Plan, Inc. Medical Necessity Criteria Page 3/3 3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) inotuzumab ozogamicin..